FIG. 1.

BAMBI expression is reduced in response to FGF-1 and during differentiation. A: Subcutaneous phPAs were grown to confluence in serum-containing medium (SCM) with either 1 ng/mL FGF-1 or 2 ng/mL platelet-derived growth factor-BB (PDGF-BB). BAMBI mRNA expression was determined by RT-PCR of total RNA. Data represent the ratio of BAMBI:cyclophilin and are the mean ± SEM of samples derived from five individuals (ANOVA, **P < 0.05 relative to control [Ctrl] SCM cells). B: SGBS PAs were grown and differentiated in the presence or absence of 1 ng/mL FGF-1. Cells were harvested at the indicated time points and BAMBI mRNA expression was measured by RT-PCR of total RNA. Data represent the ratio of BAMBI:cyclophilin and are the mean ± SEM of three to four independent experiments (ANOVA, ***P < 0.001 relative to untreated cells at differentiation day −3; Tukey #P < 0.05 for FGF-1 compared with Ctrl at day −3). C: SGBS PAs were treated with FGF-1 for the indicated times, and BAMBI mRNA expression was assessed by RT-PCR of total RNA. Data are normalized to expression at 0 h, and Ctrl represents cells harvested at 72 h without FGF-1 (mean ± SEM; n = 4 independent experiments; ANOVA, **P < 0.01; ANOVA, ***P < 0.001). D: SGBS PAs were pretreated with LY294002 or UO126 for 30 min prior to 24 h treatment with FGF-1 (in continued presence of inhibitor). BAMBI mRNA expression was determined using RT-PCR. Results are expressed as fold over vehicle-treated “Ctrl” cells (mean ± SEM; n = 3 independent experiments; **P < 0.01; ***P < 0.001).